Gilead Sciences and LEO Pharma Form Strategic Partnership to Advance STAT6 Oral Therapies for Inflammatory Diseases

-Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma  announced a strategic partnership to accelerate the development and commercializatio...

January 13, 2025 | Monday | News
Windward Bio Launches with $200M Series A Financing to Develop Breakthrough Immunology Treatments

Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...

January 12, 2025 | Sunday | News
Samsung Bioepis and Teva Forge Strategic Partnership for U.S. Launch of EPYSQLI® Biosimilar

Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the companies have entered into a license, developm...

January 13, 2025 | Monday | News
NextCure Doses First Patient in Phase 1 Study of LNCB74, a Promising Cancer Therapy

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-c...

January 13, 2025 | Monday | News
World Orphan Drug Alliance Expands Global Reach with New Partners in Canada and Latin America

The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and speci...

January 13, 2025 | Monday | News
Veralox Therapeutics Acquires Nudge Therapeutics to Advance Preclinical cGAS Inhibitor Compounds

 Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, anno...

January 10, 2025 | Friday | News
Timberlyne Therapeutics Secures $180 Million in Series A Financing to Advance CM313 for Autoimmune Diseases

Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, announced the c...

January 10, 2025 | Friday | News
Exelixis Announces FDA Update on sNDA for CABOMETYX® in Advanced pNET and epNET

 Exelixis, Inc. (Nasdaq: EXEL) announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New ...

January 10, 2025 | Friday | News
Samsung Biologics Expands Collaboration with LigaChem Biosciences to Enhance ADC Development and Manufacturing

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced to extend collaboration with L...

January 09, 2025 | Thursday | News
Xentria Expands Global Clinical Trials and Biosimilar Portfolio in 2025

Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical needs, announced operational expansion ...

January 09, 2025 | Thursday | News
FDA Accepts Revised sNDA for Astellas' IZERVAY™ in Treatment of Geographic Atrophy

 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced the U.S. Food and Drug Administration (FDA) a...

January 09, 2025 | Thursday | News
Agios Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for PYRUKYND® in Thalassemia Treatment

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

January 09, 2025 | Thursday | News
Eyebright Medical’s Loong Crystal PR Intraocular Lens Receives NMPA Class III Medical Device Certification

Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collective...

January 08, 2025 | Wednesday | News
Positive SIRONA Study Results Highlight Sirolimus-Coated Balloons as Effective Alternative to Paclitaxel for PAD Treatment

Concept Medical Inc., a global leader in innovative drug delivery technologies, is proud to report positive results from the SIRONA (Head-to-Head...

January 08, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close